BGNE - BeiGene, Ltd.
165.54 0.00 (0.00%)
After hours: 4:44PM EDT
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 162.36 |
| Open | 162.70 |
| Bid | 152.16 x 1100 |
| Ask | 165.52 x 4000 |
| Day's Range | 158.61 - 167.58 |
| 52 Week Range | 113.01 - 210.35 |
| Volume | 451,268 |
| Avg. Volume | 349,630 |
| Market Cap | 12.581B |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -17.75 |
| Earnings Date | Aug 07, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 196.60 |
- GlobeNewswire
BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
- Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated.
- GlobeNewswire
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpointCompany to host investor conference call and webcast on ASCO clinical.
- GlobeNewswire
BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
CAMBRIDGE, Mass. and BEIJING, China, May 26, 2020 -- CAMBRIDGE, Mass. and BEIJING, China, May 22, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage.
- SmarterAnalyst
Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment
Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers.The collaboration will evaluate the safety, tolerability and efficacy of two of Chi-Med’s drug candidates, surufatinib and fruquintinib, combined with BeiGene’s anti-PD-1 antibody tislelizumab for cancer treatment in the US, Europe, China and Australia.Chi-Med and BeiGene each plan to explore development of the combination of these drug candidates in different indications and regions. The companies have agreed to provide mutual drug supply and other support.“We hope to understand and develop innovative combination therapies that may bring meaningful treatments to cancer patients around the world. Through this collaboration we plan to further evaluate tislelizumab in combination with oral VEGFR inhibitors to target a variety of solid tumor cancers,” said Lai Wang of BeiGene.Each of these three compounds are currently in late-stage global clinical development across many countries outside of China. Tislelizumab and fruquintinib have both been approved by the China National Medical Products Administration which is also currently reviewing the New Drug Application for surufatinib that was submitted late last year.Both companies currently score a bullish Strong Buy Street consensus. For instance, in the last three months, six analysts have published buy ratings on BeiGene vs 1 hold rating. With shares down 4% year-to-date, the average analyst price target indicates upside potential of 19%. (See BeiGene stock analysis on TipRanks).Maxim Group’s Jason McCarthy has a buy rating on BGNE with a $190 price target. He notes that Tislelizumab is currently being evaluated in 15 registration-enabling clinical trials in China and globally (11 P3 and 4 pivotal P2 trials).Related News: Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July Regeneron and Sanofi’s Dupixent Shows ‘Positive’ Trial Data, Meets Co-Primary Endpoints Regeneron To Repurchase $5 Billion Stake From Sanofi More recent articles from Smarter Analyst: * 5-Star Analyst Pounds the Table on Roku Stock * Efgartigimod's Positive Data Is Good News for Momenta’s Nipocalimab * Elon Musk Reaps Payout Worth $775M, As Analyst Admits Tesla Is ‘Turning A Corner’ * Costco Pulls Back On Earnings; Top Analyst Sees Buying Opportunity
- GlobeNewswire
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
– Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China.
- GlobeNewswire
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on.
- GlobeNewswire
BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
- GlobeNewswire
BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
- Investor's Business Daily
Growth Stocks Like Amazon And Tesla Share These Key Metrics: Advisor
Simon Erickson of 7Investing.com joined the podcast this week to discuss the key metrics he uses to identify power growth stocks like Amazon and Tesla.
- GlobeNewswire
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
- GlobeNewswire
BeiGene Reports First Quarter 2020 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, May 11, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
- GlobeNewswire
BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
- GlobeNewswire
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene’s anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). “We look forward to working closely with the CDE on this filing and hope to bring a new treatment option to the large population of patients with advanced squamous NSCLC in China who could benefit from immunotherapy.”
- GlobeNewswire
BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC) met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) compared to pemetrexed and platinum chemotherapy alone at the planned interim analysis, as assessed by independent review committee (IRC). The safety profile of tislelizumab in combination with pemetrexed and platinum chemotherapy was consistent with the known risks of each study treatment, and no new safety signals were identified.
- GlobeNewswire
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Following tislelizumab’s initial approval in classical Hodgkin’s lymphoma (cHL) by the NMPA in December 2019, this is the second indication approved for tislelizumab, and the first in a solid tumor indication.
- Business Wire
ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene may have issued materially misleading business information to the investing public.
- GlobeNewswire
BeiGene Announces Supply Update for ABRAXANE® in China
BEIJING, China, and CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, on March 25, 2020, the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in China supplied to BeiGene by Celgene Corporation, a Bristol Myers Squibb (BMS) company. This suspension is based on inspection findings at BMS’s contract manufacturing facility in the United States.
- Insider Monkey
Hedge Funds Are Betting On BeiGene, Ltd. (BGNE)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd.
- GlobeNewswire
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. – BGNE
NEW YORK, March 09, 2020 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd..
- Barrons.com
Coronavirus Outbreak Could Disrupt Drug Companies’ Clinical Trials
It could develop into a serious long-term problem for the pharmaceutical industry, which relies on clinical trials to get new drugs to the market.
- GlobeNewswire
BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, March 02, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
MapKure, LLC, a clinical-stage company developing precision medicines for patients with life-threatening diseases, together with BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and SpringWorks Therapeutics, Inc. (SWTX), who are joint owners of MapKure, announced today that the first patient has been dosed in Australia in a Phase 1 clinical trial to evaluate BGB-3245, an investigational, next-generation B-RAF inhibitor, in patients with advanced or refractory solid tumors. The companies also announced that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) application submitted for BGB-3245 to proceed, which will enable study expansion to U.S. sites.
- GlobeNewswire
BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference
CAMBRIDGE, Mass. and BEIJING, China, Feb. 25, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Moody's
Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured note offering of Amgen Inc. ("Amgen"). There are no changes to the existing ratings of Amgen including the Baa1 senior unsecured long-term rating and the Prime-2 short-term rating. Amgen's Baa1 rating reflects its position as the largest stand-alone biotechnology company, its high margins and its good cash flow.
